Molbio Diagnostics Q1FY27 Results: Net profit up 523% YoY to ₹527.44 million
- Consolidated net profit surged to ₹587.47 million in Q1FY27 from a loss of ₹237.14 million in Q1FY25
- Revenue grew 309% YoY to ₹4,083.76 million, driven by strong operational performance
- Company completed IPO in August 2026, raising ₹2,000 million via fresh issue
- Increased stake in Prognosys Medical Systems to 70% during the quarter
- Basic EPS improved to ₹5.21 from a loss of ₹2.10 per share in the prior year
*this image is generated using AI for illustrative purposes only.
The Board of Directors of Molbio Diagnostics approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on September 5, 2026. The diagnostics manufacturer reported a significant turnaround in profitability, driven by robust revenue growth following its recent public listing.
Financial Performance
Consolidated revenue from operations for Q1FY27 stood at ₹4,083.76 million, a substantial increase from ₹997.08 million in the corresponding quarter of FY26. Standalone revenue was recorded at ₹3,993.78 million, compared to ₹953.20 million in Q1FY25. The group reported a consolidated net profit attributable to owners of the parent company of ₹587.47 million, reversing a net loss of ₹237.14 million in the same period last year. Standalone net profit for the quarter was ₹566.27 million, up from a loss of ₹134.05 million in Q1FY25.
| Metric | Consolidated Q1FY27 | Consolidated Q1FY25 | Standalone Q1FY27 | Standalone Q1FY25 |
|---|---|---|---|---|
| Revenue (₹ Million) | 4,083.76 | 997.08 | 3,993.78 | 953.20 |
| Net Profit/Loss (₹ Million) | 527.44 | (239.44) | 566.27 | (134.05) |
| EPS (₹) | 5.21 | (2.10) | 5.02 | (1.19) |
The basic and diluted earnings per share (EPS) for the consolidated entity were ₹5.21, compared to a loss of ₹2.10 per share in Q1FY25. For the standalone entity, EPS was ₹5.02, against a loss of ₹1.19 per share in the prior year quarter. The comparative figures for Q1FY25 have been retrospectively adjusted for a 4:1 bonus issue allotted in September 2025.
What the Numbers Show
A notable divergence exists between the standalone and consolidated results regarding other income. While standalone other income declined to ₹13.68 million from ₹14.82 million in Q1FY25, consolidated other income more than quadrupled to ₹31.00 million from ₹7.60 million. This suggests that subsidiaries or associates contributed significantly to non-operating income in the current quarter, offsetting the slight dip at the holding company level.
Corporate Developments
Subsequent to the quarter ended June 30, 2026, Molbio Diagnostics completed its Initial Public Offer (IPO). The issue comprised 11,646,246 equity shares, including a fresh issue of 2,480,246 shares aggregating to ₹2,000.00 million and an offer for sale by existing shareholders aggregating to ₹7,396.96 million. The shares were listed on the NSE and BSE on August 17, 2026, at an issue price of ₹807 per share for investors and ₹731 for employees.
During the quarter, the company increased its stake in Prognosys Medical Systems Private Limited (PMS) from 65.47% to 70.00% by acquiring an additional 4.53% stake. Earlier in FY26, Molbio had converted its associate interest in OptraSCAN Inc. into a subsidiary by increasing its holding to 60%, effective November 1, 2025.
Regulatory and Tax Matters
The company disclosed an ongoing survey under Section 133A of the Income-tax Act, 1961. The tax department has raised demands aggregating to ₹208.71 million plus interest and penalty for assessment years 2020-21 to 2024-25. Molbio has appealed to the Commissioner of Income Tax (Appeals) and paid ₹78.95 million under protest as of June 30, 2026. Management expressed confidence in a favorable outcome and made no adjustments in the financial results.
Additionally, the board authorized Key Managerial Personnel (KMPs), including CEO Sriram Natarajan and CFO Manan Bimal Khokhani, to determine the materiality of events for disclosure under SEBI Listing Regulations.
Historical Stock Returns for Molbio Diagnostics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.23% | +1.43% | 0.0% | 0.0% | 0.0% | 0.0% |
How will the substantial cash inflow from the recent IPO be allocated between debt repayment, R&D expansion, and potential M&A activities in the coming quarters?
What is the strategic rationale behind increasing the stake in Prognosys Medical Systems to 70%, and how will this consolidation impact future revenue recognition and operational synergies?
Could the ongoing income tax survey and the ₹208.71 million demand pose a material risk to Molbio's liquidity or credit rating, despite management's confidence in a favorable appeal outcome?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
